| Revision as of 10:35, 9 December 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProje...← Previous edit |
Latest revision as of 20:47, 1 December 2023 edit undoBuidhe (talk | contribs)Autopatrolled, Extended confirmed users, Page movers, File movers, Mass message senders, New page reviewers, Pending changes reviewers, Template editors136,068 editsm Moving from Category:Experimental drugs to Category:Experimental monoclonal antibodies using Cat-a-lot |
| (13 intermediate revisions by 12 users not shown) |
| Line 1: |
Line 1: |
|
⚫ |
{{Short description|Monoclonal antibody}} |
|
{{Drugbox |
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
| verifiedrevid = 464214206 |
|
| verifiedrevid = 464214206 |
|
| image = |
|
| image = |
|
|
<!-- Monoclonal antibody data --> |
|
|
|
| ⚫ |
<!--Monoclonal antibody data--> |
|
|
| type = mab |
|
| type = mab |
|
| mab_type = mab |
|
| mab_type = mab |
|
| source = xi/o |
|
| source = xi/o |
|
| target = ] |
|
| target = ] |
|
⚫ |
<!-- Clinical data --> |
|
|
|
| ⚫ |
<!--Clinical data--> |
|
|
| tradename = |
|
| tradename = |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_category = |
|
| pregnancy_category = |
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> |
|
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
|
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
| Line 21: |
Line 20: |
|
| legal_status = |
|
| legal_status = |
|
| routes_of_administration = |
|
| routes_of_administration = |
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID = NA |
|
| ChemSpiderID = none |
|
⚫ |
<!-- Pharmacokinetic data --> |
|
|
|
| ⚫ |
<!--Pharmacokinetic data--> |
|
|
| bioavailability = |
|
| bioavailability = |
|
| protein_bound = |
|
| protein_bound = |
|
| metabolism = |
|
| metabolism = |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| excretion = |
|
| excretion = |
|
⚫ |
<!-- Identifiers --> |
|
|
|
|
⚫ |
| CAS_number_Ref = {{cascite|changed|CAS}} |
| ⚫ |
<!--Identifiers--> |
|
| ⚫ |
| CAS_number_Ref = {{cascite|changed|??}} |
|
|
| CAS_number = 147191-91-1 |
|
| CAS_number = 147191-91-1 |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = TW5DE23BLM |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
|
| PubChem = |
|
| PubChem = |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
| DrugBank = |
|
⚫ |
<!-- Chemical data --> |
|
|
|
|
⚫ |
| chemical_formula = |
| ⚫ |
<!--Chemical data--> |
|
| ⚫ |
| chemical_formula = |
|
|
|
|
|
| molecular_weight = |
|
| molecular_weight = |
|
}} |
|
}} |
|
'''Priliximab''' (cMT 412) is a human-mouse chimeric anti-CD4 ]. It has been tested on patients with ]<ref>{{cite journal |author=Stronkhorst A, Radema S, Yong S, Bijl H, ten Berge I, Tytgat G, van Deventer S |title=CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study |journal=Gut |volume=40 |issue=3 |pages=320–7 |year=1997 |pmid=9135519 |pmc=1027080}}</ref> and ]<ref>{{cite journal |author=Llewellyn-Smith N, Lai M, Miller D, Rudge P, Thompson A, Cuzner M |title=Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412 |journal=Neurology |volume=48 |issue=4 |pages=810–6 |year=1997 |pmid=9109860}}</ref><ref>{{cite journal |author=van Oosten B, Lai M, Hodgkinson S, Barkhof F, Miller D, Moseley I, Thompson A, Rudge P, McDougall A, McLeod J, Adèr H, Polman C |title=Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial |journal=Neurology |volume=49 |issue=2 |pages=351–7 |year=1997 |pmid=9270561}}</ref> but has not yet received ] licencing. The patent belongs to the biotechnology company ]. |
|
'''Priliximab''' (cMT 412) is a human-mouse chimeric anti-CD4 ]. It has been tested on patients with ]<ref>{{cite journal |vauthors=Stronkhorst A, Radema S, Yong S, Bijl H, ten Berge I, Tytgat G, van Deventer S |title=CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study |journal=Gut |volume=40 |issue=3 |pages=320–7 |year=1997 |pmid=9135519 |pmc=1027080|doi=10.1136/gut.40.3.320 }}</ref> and ]<ref>{{cite journal |vauthors=Llewellyn-Smith N, Lai M, Miller D, Rudge P, Thompson A, Cuzner M |title=Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412 |journal=Neurology |volume=48 |issue=4 |pages=810–6 |year=1997 |pmid=9109860 |doi=10.1212/wnl.48.4.810|s2cid=9938490 }}</ref><ref>{{cite journal |vauthors=van Oosten B, Lai M, Hodgkinson S, Barkhof F, Miller D, Moseley I, Thompson A, Rudge P, McDougall A, McLeod J, Adèr HJ, Polman C |author11-link=Herman J. Adèr |title=Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial |journal=Neurology |volume=49 |issue=2 |pages=351–7 |year=1997 |pmid=9270561 |doi=10.1212/wnl.49.2.351|s2cid=8294890 }}</ref> but has not yet received ] licensing. The patent belongs to the biotechnology company ]. |
|
|
|
|
|
==References== |
|
==References== |
| Line 52: |
Line 49: |
|
{{Monoclonals for immune system}} |
|
{{Monoclonals for immune system}} |
|
|
|
|
|
] |
|
] |
|
|
] |
|
|
|
|
|
|
|
{{monoclonal-antibody-stub}} |
|
{{monoclonal-antibody-stub}} |
|
{{antineoplastic-drug-stub}} |
|
{{antineoplastic-drug-stub}} |
